Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa High-Dollar Drug Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.01.93

    High Dollar Drug Review

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.01.93 alerts

    Get alerted when Policy 05.01.93 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Review of high-dollar pharmacy and medical drug claims for clinical appropriateness, dosing, quantity, duration, coding, billed units, and cost when drugs are not already managed under drug-specific prior authorization criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyHigh Dollar Drug Review
    Policy CodePolicy 05.01.93
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 27, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis and clinically appropriate use of the requested drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    $34,999.99Pharmacy claim review threshold
    $100,000Medical claim review threshold
    12 monthsMaximum approval duration
    5Initial approval criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy

    Covered when ALL of the following initial approval criteria are met.

    Initial approval criteria

    • Indication: The requested drug must be used for an FDA-approved indication or an indication supported in the compendia of current literature.

      Examples include AHFS, Micromedex, and current accepted guidelines.

    • Dose, frequency, and duration: The prescribed quantity, dosing frequency, and duration must fall within the manufacturer's published dosing guidelines or dosing guidelines in the compendia of current literature.

      Examples include the package insert, AHFS, Micromedex, and current accepted guidelines.

    • Standard therapy: The patient must have experienced an inadequate response, intolerance, or contraindication to clinically appropriate standard therapies before the requested drug when such alternatives exist and are appropriate for the member's condition.
    • Documentation: The provider must submit necessary documentation supporting the diagnosis and clinically appropriate use of the drug.
    • Billed quantity: The billed quantity must align with the smallest available dose that can effectively deliver the prescribed dosage to the patient.

    Continuation therapy

    Covered for continuation when ALL of the following are met.

    Continuation therapy criteria

    • Initial criteria remain satisfied: All initial approval criteria are met.
    • Positive clinical response: Clinical documentation shows that the patient has achieved and/or maintained a positive clinical response with the requested therapy.

    High-Dollar Claim Review Thresholds

    Pharmacy claim review
    Review threshold> $34,999.99 per pharmacy claim
    Review focusClinically appropriate quantity, dose, frequency, duration, coding, billed units, and cost
    Policy purposePromote safe, clinically appropriate, and cost-effective use of the requested drug(s)
    Medical claim review
    Review threshold>= $100,000 per medical claim
    Review focusClinically appropriate quantity, dose, frequency, duration, coding, billed units, and cost
    Policy purposeAssist in applying safeguards against unnecessary utilization of medications

    Provider Requirements and Review Outcomes

    Prior Authorization

    High-Dollar Drug Review and Initial Approval

    Submit high-dollar drug claims for review when they exceed $34,999.99 per pharmacy claim or $100,000 per medical claim. Initial approval requires all applicable medical-necessity and billing criteria, and approval is limited to the FDA-approved or compendia-supported treatment duration, not to exceed 12 months.

    • Review applies to drugs not currently managed through drug-specific prior authorization criteria, unless a change after drug-specific approval requires further review.
    • Use an FDA-approved indication or an indication supported by current compendia of literature.
    • Ensure quantity, dose, frequency, duration, and billed units or cost are clinically appropriate and within manufacturer or compendia dosing guidelines.
    • Bill the smallest available dose that can effectively deliver the prescribed dosage.
    Prior Authorization

    Continuation Authorization

    For continuation requests, resubmit documentation demonstrating that the patient has achieved and/or maintained a positive clinical response to the requested therapy. All initial authorization criteria must continue to be met; approval may not exceed 12 months.

    • Use an FDA-approved treatment duration or a duration supported by current compendia of literature.
    • Include clinical evidence of response with every continuation request.
    Denial Risk

    Insufficient Continuation Response Documentation

    Continuation authorization is at risk when the submission does not document that the patient has achieved or maintained a positive clinical response with the requested therapy.

    • Provide current clinical documentation demonstrating positive response to treatment.
    • If response is not documented, continuation criteria are not satisfied.
    Documentation Required

    Diagnosis and Clinical-Use Documentation

    Submit provider documentation supporting the patient's diagnosis and the clinically appropriate use of the requested drug. The indication must be FDA-approved or supported by current compendia of literature.

    • Examples of supporting compendia include AHFS, Micromedex, and current accepted guidelines.
    • Documentation must connect the diagnosis and clinical use to the requested therapy.
    Step Therapy

    Standard Therapy Prerequisite

    Before requesting the drug, document that the patient experienced an inadequate response, intolerance, or contraindication to clinically appropriate standard therapies when appropriate alternatives exist for the member's condition.

    • The prerequisite applies before the requested drug.
    • Standard therapy must be clinically appropriate and an available alternative for the member's condition.
    Denial Risk

    Failure to Meet Medical Necessity and Billing Criteria

    Medical necessity and payment may be denied when the requested use or claim does not meet the policy's indication, dosing, duration, quantity, coding, billed-unit, or cost requirements.

    • Use an FDA-approved or compendia-supported indication.
    • Keep quantity, dose, frequency, and duration within manufacturer or compendia guidelines.
    • Ensure billed quantity aligns with the smallest available dose that can effectively deliver the prescribed dosage.
    • High-dollar review thresholds are $34,999.99 per pharmacy claim and $100,000 per medical claim.
    Denial Risk

    Continuation Response Documentation Required

    A continuation request may be denied when the provider does not submit documentation showing that the patient has achieved and/or maintained a positive clinical response with the requested therapy.

    • Positive clinical response documentation is required in addition to meeting all initial authorization criteria.
    • Approval is limited to the FDA-approved or compendia-supported duration and may not exceed 12 months.

    Policy Background

    This policy promotes the safe, clinically appropriate, and cost-effective use of high-dollar drugs. Review assesses whether the requested drug’s indication, quantity, dose, frequency, duration, coding, billed units, and cost are consistent with FDA-approved labeling, accepted compendia, or evidence-based practice guidelines. It also supports safeguards against unnecessary medication utilization and encourages prescribing quantities consistent with applicable dosing guidance.

    Key Definitions

    High-dollar drug claim
    Pharmacy claim thresholdExceeds $34,999.99 per pharmacy claim
    Medical claim thresholdExceeds $100,000 per medical claim
    Review scopeDrugs subject to review for clinically appropriate quantity, dose, frequency, duration, coding, billed units, or cost
    Drug-specific prior authorization criteria
    Existing managementDrug-specific prior authorization criteria that already manage a drug
    High-dollar review scopeApplies to drugs not currently managed through drug-specific prior authorization criteria
    ExceptionFurther review may be required when a change occurs after drug-specific prior authorization approval

    Initial Therapy

    Initial therapy criteria

    Initial therapy may be considered medically necessary when ALL of the following requirements are met.

    Initial therapy: The requested drug must have an FDA-approved or compendia-supported indication; the prescribed quantity, dosing frequency, and duration must follow manufacturer or compendia guidance; appropriate standard therapies must have resulted in an inadequate response, intolerance, or contraindication when available and appropriate; required diagnosis and clinical-use documentation must be submitted; and the billed quantity must align with the smallest available dose that can effectively deliver the prescribed dosage.

    Approval will be for the FDA-approved duration or a compendia-supported duration not exceeding 12 months.

    Continuation Therapy

    Continuation therapy criteria

    Continuation therapy may be considered medically necessary when ALL of the following requirements are met.

    Continuation therapy

    • Initial authorization criteria: All initial authorization criteria are met.
    • Positive clinical response: Clinical documentation shows that the patient has achieved and/or maintained a positive clinical response with the requested therapy.

    Standard Therapy Prerequisite

    StepRequirementFailure criteria
    1Try clinically appropriate standard therapies before the requested drug when such alternatives exist and are appropriate for the member’s condition.Inadequate response, intolerance, or contraindication to the standard therapy.

    Duration and Quantity Limits

    Requested high-dollar drug
    Maximum treatment durationFDA-approved duration or a compendia-supported duration not exceeding 12 months
    Duration basisFDA-approved product labeling or compendia of current literature
    Dosing limitsApprovals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyHigh Dollar Drug Review
    Policy CodePolicy 05.01.93
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 27, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis and clinically appropriate use of the requested drug.
    SourceLink
    On This Page
    Coverage CriteriaHigh-Dollar Claim Review ThresholdsProvider Requirements and Review OutcomesPolicy BackgroundKey DefinitionsInitial TherapyContinuation TherapyStandard Therapy PrerequisiteDuration and Quantity Limits